Statistics in Medicine

• 

  Publication Venue For

  • A Bayesian approach for individual-level drug benefit-risk assessment. 2019
  • Power and sample size requirements for GEE analyses of cluster randomized crossover trials..  38:636-649. 2019
  • Single-number summary and decision analytic measures can happily coexist..  38:499-500. 2019
  • Sample size calculation for studies with grouped survival data..  37:3904-3917. 2018
  • Simultaneous record linkage and causal inference with propensity score subclassification..  37:3533-3546. 2018
  • Auxiliary variable-enriched biomarker-stratified design. 2018
  • Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks..  37:1389-1401. 2018
  • Accommodating the ecological fallacy in disease mapping in the absence of individual exposures..  36:4930-4942. 2017
  • Authors' response to comments..  36:4511-4513. 2017
  • Discrimination slope and integrated discrimination improvement - properties, relationships and impact of calibration..  36:4482-4490. 2017
  • Net reclassification index at event rate: properties and relationships..  36:4455-4467. 2017
  • An evaluation of constrained randomization for the design and analysis of group-randomized trials with binary outcomes..  36:3791-3806. 2017
  • Asymptotic distribution of ∆AUC, NRIs, and IDI based on theory of U-statistics..  36:3334-3360. 2017
  • Functional joint model for longitudinal and time-to-event data: an application to Alzheimer's disease..  36:3560-3572. 2017
  • Multidimensional latent trait linear mixed model: an application in clinical studies with multivariate longitudinal outcomes..  36:3244-3256. 2017
  • On assessing bioequivalence and interchangeability between generics based on indirect comparisons..  36:2978-2993. 2017
  • A comparison of risk prediction methods using repeated observations: an application to electronic health records for hemodialysis..  36:2750-2763. 2017
  • Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials..  36:403-415. 2017
  • Comments on 'Estimands in clinical trials - broadening the perspective'..  36:24-26. 2017
  • Methods for assessing the reliability of quality of life based on SF-36..  35:5656-5665. 2016
  • Modeling zero-modified count and semicontinuous data in health services research Part 1: background and overview..  35:5070-5093. 2016
  • Modeling zero-modified count and semicontinuous data in health services research part 2: case studies..  35:5094-5112. 2016
  • Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study..  35:4824-4836. 2016
  • Robust analysis of secondary phenotypes in case-control genetic association studies..  35:4226-4237. 2016
  • Assessing agreement with relative area under the coverage probability curve..  35:3153-3165. 2016
  • Bayesian multinomial probit modeling of daily windows of susceptibility for maternal PM2.5 exposure and congenital heart defects..  35:2786-2801. 2016
  • Bayesian reclassification statistics for assessing improvements in diagnostic accuracy..  35:2574-2592. 2016
  • A hidden Markov model approach to analyze longitudinal ternary outcomes when some observed states are possibly misclassified..  35:1549-1557. 2016
  • Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy..  35:1245-1256. 2016
  • Multiple imputation for harmonizing longitudinal non-commensurate measures in individual participant data meta-analysis..  34:3399-3414. 2015
  • Numeric score-based conditional and overall change-in-status indices for ordered categorical data..  34:3622-3636. 2015
  • Incorporation of individual-patient data in network meta-analysis for multiple continuous endpoints, with application to diabetes treatment..  34:2794-2819. 2015
  • Scan-stratified case-control sampling for modeling blood-brain barrier integrity in multiple sclerosis..  34:2872-2880. 2015
  • A spatiotemporal quantile regression model for emergency department expenditures..  34:2559-2575. 2015
  • Comparison of operational characteristics for binary tests with clustered data..  34:2325-2333. 2015
  • Placebo non-response measure in sequential parallel comparison design studies..  34:2281-2293. 2015
  • Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations..  34:406-431. 2015
  • Comparison of operational characteristics for binary tests with clustered data 2015
  • What to expect from net reclassification improvement with three categories.  33:4975-4987. 2014
  • A marginalized two-part model for semicontinuous data..  33:4891-4903. 2014
  • A marginalized zero-inflated Poisson regression model with overall exposure effects..  33:5151-5165. 2014
  • What to expect from net reclassification improvement with three categories..  33:4975-4987. 2014
  • Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease..  33:4279-4291. 2014
  • How to interpret a small increase in AUC with an additional risk prediction marker: Decision analysis comes through.  33:3946-3959. 2014
  • How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through..  33:3946-3959. 2014
  • Adjusting for misclassification in a stratified biomarker clinical trial.  33:3100-3113. 2014
  • Adjusting for misclassification in a stratified biomarker clinical trial..  33:3100-3113. 2014
  • Net reclassification improvement and integrated discrimination improvement require calibrated models: relevance from a marker and model perspective..  33:3415-3418. 2014
  • Assessing the incremental predictive performance of novel biomarkers over standard predictors.  33:2577-2584. 2014
  • Assessing the incremental predictive performance of novel biomarkers over standard predictors..  33:2577-2584. 2014
  • Joint model for a diagnostic test without a gold standard in the presence of a dependent terminal event..  33:2554-2566. 2014
  • Imputation of confidential data sets with spatial locations using disease mapping models..  33:1928-1945. 2014
  • Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test..  33:2004-2016. 2014
  • A global logrank test for adaptive treatment strategies based on observational studies.  33:760-771. 2014
  • Incidence estimation using a single cross-sectional age-specific prevalence survey with differential mortality.  33:422-435. 2014
  • A Bayesian approach to joint analysis of multivariate longitudinal data and parametric accelerated failure time..  33:580-594. 2014
  • A global logrank test for adaptive treatment strategies based on observational studies..  33:760-771. 2014
  • Incidence estimation using a single cross-sectional age-specific prevalence survey with differential mortality..  33:422-435. 2014
  • A marginalized two-part model for semicontinuous data.  33:4891-4903. 2014
  • Correction to How to interpret a small increase in AUC with an additional risk prediction marker: Decision analysis comes through [Statist. Med. (2015) 33, 22, 3946-3959] DOI: 10.1002/sim.6195.  34:900. 2014
  • Imputation of confidential data sets with spatial locations using disease mapping models.  33:1928-1945. 2014
  • What to expect from net reclassification improvement with three categories 2014
  • A hybrid method in combining treatment effects from matched and unmatched studies..  32:4924-4937. 2013
  • Joint analysis of stochastic processes with application to smoking patterns and insomnia..  32:5133-5144. 2013
  • Designs for randomized phase II clinical trials with two treatment arms..  32:4367-4379. 2013
  • On model specification and selection of the Cox proportional hazards model..  32:4609-4623. 2013
  • A latent factor linear mixed model for high-dimensional longitudinal data analysis..  32:4229-4239. 2013
  • Impact of correlation on predictive ability of biomarkers..  32:4196-4210. 2013
  • Robust Bayesian inference for multivariate longitudinal data by using normal/independent distributions..  32:3812-3828. 2013
  • Propensity score weighting with multilevel data..  32:3373-3387. 2013
  • A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies..  32:2767-2789. 2013
  • A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer..  32:2320-2334. 2013
  • A weighted generalized score statistic for comparison of predictive values of diagnostic tests..  32:964-977. 2013
  • An adapted F-test for homogeneity of variability in follow-on biological products..  32:415-423. 2013
  • Application of the parallel line assay to assessment of biosimilar products based on binary endpoints..  32:449-461. 2013
  • Assessing biosimilarity and interchangeability of biosimilar products..  32:361-363. 2013
  • Comments on the FDA draft guidance on biosimilar products..  32:364-369. 2013
  • Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics..  32:424-433. 2013
  • On the interchangeability of biologic drug products..  32:434-441. 2013
  • Scientific considerations for assessing biosimilar products..  32:370-381. 2013
  • Statistical assessment of biosimilarity based on relative distance between follow-on biologics..  32:382-392. 2013
  • Statistical methods for assessing interchangeability of biosimilars..  32:442-448. 2013
  • The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics..  32:406-414. 2013
  • A weighted generalized score statistic for comparison of predictive values of diagnostic tests.  32:964-977. 2013
  • An adapted F-test for homogeneity of variability in follow-on biological products.  32:415-423. 2013
  • Application of the parallel line assay to assessment of biosimilar products based on binary endpoints.  32:449-461. 2013
  • Comments on the FDA draft guidance on biosimilar products.  32:364-369. 2013
  • Designs for randomized phase II clinical trials with two treatment arms.  32:4367-4379. 2013
  • Impact of correlation on predictive ability of biomarkers.  32:4196-4210. 2013
  • Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics.  32:424-433. 2013
  • On model specification and selection of the Cox proportional hazards model.  32:4609-4623. 2013
  • On the interchangeability of biologic drug products.  32:434-441. 2013
  • Phase II clinical trials with time-to-event endpoints: Optimal two-stage designs with one-sample log-rank test 2013
  • Propensity score weighting with multilevel data.  32:3373-3387. 2013
  • Scientific considerations for assessing biosimilar products.  32:370-381. 2013
  • Statistical assessment of biosimilarity based on relative distance between follow-on biologics.  32:382-392. 2013
  • Statistical methods for assessing interchangeability of biosimilars.  32:442-448. 2013
  • The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics.  32:406-414. 2013
  • A comparison of least squares and conditional maximum likelihood estimators under volume endpoint censoring in tumor growth experiments..  31:4061-4073. 2012
  • Adverse subpopulation regression for multivariate outcomes with high-dimensional predictors..  31:4102-4113. 2012
  • Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials..  31:3789-3804. 2012
  • Misuse of DeLong test to compare AUCs for nested models..  31:2577-2587. 2012
  • A new permutation-based method for assessing agreement between two observers making replicated quantitative readings..  31:2249-2261. 2012
  • A spatio-temporal absorbing state model for disease and syndromic surveillance..  31:2123-2136. 2012
  • Bayesian semiparametric regression models for evaluating pathway effects on continuous and binary clinical outcomes..  31:1633-1651. 2012
  • Designing a pilot sequential multiple assignment randomized trial for developing an adaptive treatment strategy..  31:1887-1902. 2012
  • Quantifying discrimination of Framingham risk functions with different survival C statistics..  31:1543-1553. 2012
  • Sensitivity analysis for unmeasured confounding in principal stratification settings with binary variables..  31:949-962. 2012
  • Correction: Evaluation metrics for biostatistical and epidemiological collaborations.  31:600. 2012
  • Authors' reply.  31:96-97. 2012
  • A framework for quantifying net benefits of alternative prognostic models..  31:114-130. 2012
  • Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease..  31:29-44. 2012
  • Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models..  31:101-113. 2012
  • Assessing agreement with repeated measures for random observers..  30:3546-3559. 2011
  • A min-max combination of biomarkers to improve diagnostic accuracy.  30:3266. 2011
  • The end of the beginning: A commentary on 'Evaluation metrics for biostatistical and epidemiological collaborations': A rejoinder.  30:2783-2784. 2011
  • Evaluation metrics for biostatistical and epidemiological collaborations..  30:2767-2777. 2011
  • A Bayesian growth mixture model to examine maternal hypertension and birth outcomes..  30:2721-2735. 2011
  • A few remarks on 'Statistical distribution of the difference of two proportions' by Nadarajah and Kotz, Statistics in Medicine 2007; 26(18):3518-3523..  30:1913-1915. 2011
  • A min-max combination of biomarkers to improve diagnostic accuracy..  30:2005-2014. 2011
  • Hierarchical spatial modeling of uncertainty in air pollution and birth weight study..  30:2187-2198. 2011
  • Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint..  30:1502-1518. 2011
  • Equivalence of improvement in area under ROC curve and linear discriminant analysis coefficient under assumption of normality..  30:1410-1418. 2011
  • On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data..  30:1105-1117. 2011
  • A new permutation-based method for assessing agreement between two observers making replicated binary readings..  30:839-853. 2011
  • Estimating propensity scores with missing covariate data using general location mixture models..  30:627-641. 2011
  • A rank-based sample size method for multiple outcomes in clinical trials (vol 27, pg 3084, 2008).  30:597-597. 2011
  • Erratum: A rank-based sample size method for multiple outcomes in clinical trials.  30:597. 2011
  • Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers..  30:11-21. 2011
  • Sample size calculations for evaluating a diagnostic test when the gold standard is missing at random..  30:200. 2011
  • Analysis of multi-arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models..  29:2399-2409. 2010
  • Using Testlet Response Theory to analyze data from a survey of attitude change among breast cancer survivors..  29:2028-2044. 2010
  • Joint Bayesian analysis of birthweight and censored gestational age using finite mixture models..  29:1710-1723. 2010
  • Sample size calculations for evaluating a diagnostic test when the gold standard is missing at random..  29:1572-1579. 2010
  • A bivariate survival model with compound Poisson frailty..  29:275-283. 2010
  • A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data..  29:75-85. 2010
  • Bayesian inference for the stereotype regression model: Application to a case-control study of prostate cancer..  28:3139-3157. 2009
  • Response to ‘Net reclassification improvement and decision theory’ by Vickerset al..  28:526-528. 2009
  • Semiparametric Bayesian modeling of random genetic effects in family-based association studies..  28:113-139. 2009
  • Strategies for analyzing multilevel cluster-randomized studies with binary outcomes collected at varying intervals of time..  27:6055-6071. 2008
  • Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology..  27:5525-5555. 2008
  • 'Smooth' inference for survival functions with arbitrarily censored data..  27:5421-5439. 2008
  • Bayesian bootstrap estimation of ROC curve..  27:5407-5420. 2008
  • Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach..  27:4658-4677. 2008
  • A distribution-free test of constant mean in linear mixed effects models..  27:3833-3846. 2008
  • Estimation of propensity scores using generalized additive models..  27:3805-3816. 2008
  • A rank-based sample size method for multiple outcomes in clinical trials..  27:3084-3104. 2008
  • Sample size calculation for the weighted rank statistics with paired survival data..  27:3350-3365. 2008
  • Joint modeling of sensitivity and specificity..  27:1745-1761. 2008
  • Randomized phase II trials with a prospective control..  27:568-583. 2008
  • Comments on 'Integrated discrimination and net reclassification improvements - Practical advice'.  27:207-212. 2008
  • Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond..  27:157-172. 2008
  • Morphometric analysis for early detection of changes in cellular structure in a toxicological experiment..  26:5253-5266. 2007
  • Relative quantification based on logistic models for individual polymerase chain reactions..  26:5596-5611. 2007
  • A correlated frailty model with long-term survivors for estimating the heritability of breast cancer..  26:3722-3734. 2007
  • Analysis on binary responses with ordered covariates and missing data..  26:3443-3458. 2007
  • Bayesian methods for searching for optimal rules for timing intercourse to achieve pregnancy..  26:1920-1936. 2007
  • Bivariate random effect model using skew-normal distribution with application to HIV-RNA.  26:1255-1267. 2007
  • A multivariate test for population bioequivalence..  26:1208-1223. 2007
  • Bivariate random effect model using skew-normal distribution with application to HIV-RNA..  26:1255-1267. 2007
  • Choice of time scale and its effect on significance of predictors in longitudinal studies..  26:1343-1359. 2007
  • Performance assessment for radiologists interpreting screening mammography..  26:1532-1551. 2007
  • Stability analysis for drugs with multiple active ingredients..  26:1512-1517. 2007
  • Inference for case-control studies when exposure status is both informatively missing and misclassified..  25:4065-4080. 2006
  • Bayesian semi-parametric ROC analysis..  25:3905-3928. 2006
  • Estimating measures of diagnostic accuracy when some covariate information is missing..  25:2981-2993. 2006
  • Interval estimation for treatment effects using propensity score matching..  25:2230-2256. 2006
  • Author's reply [4].  25:1437-1438. 2006
  • On non-inferiority margin and statistical tests in active control trials..  25:1101-1113. 2006
  • Rank tests for clustered survival data when dependent subunits are randomized..  25:361-373. 2006
  • Examining accuracy of screening mammography using an event order model..  25:267-283. 2006
  • Assay validation for left-censored data..  24:3347-3360. 2005
  • A multiple testing procedure to associate gene expression levels with survival..  24:3077-3088. 2005
  • Sample size for a two-group comparison of repeated binary measurements using GEE..  24:2583-2596. 2005
  • Statistical inference for cancer trials with treatment switching..  24:1783-1790. 2005
  • Assessing intra, inter and total agreement with replicated readings..  24:1371-1384. 2005
  • Analysis of clinical data with breached blindness: by Shein-Chung Chow and Jun Shao Statistics in Medicine 2004; 23:1185-1193..  24:819-821. 2005
  • A practical approach for comparing means of two groups without equal variance assumption: H. Wang and S. Chow, Statistics in Medicine 2002; 21:3137-3151..  24:817-818. 2005
  • Strength of accumulating evidence and data monitoring committee decision making..  23:2659-2672. 2004
  • Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation..  23:2109-2123. 2004
  • Odds ratios for a continuous outcome variable without dichotomizing..  23:1843-1860. 2004
  • Sample size determination for comparing several survival curves with unequal allocations..  23:1793-1815. 2004
  • Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?.  23:1503-1505. 2004
  • Analysis of clinical data with breached blindness..  23:1185-1193. 2004
  • On the estimation of the binomial probability in multistage clinical trials..  23:881-896. 2004
  • Admissible two-stage designs for phase II cancer clinical trials..  23:561-569. 2004
  • Growth velocity assessment in paediatric AIDS: smoothing, penalized quantile regression and the definition of growth failure..  23:509-526. 2004
  • The heritability of cause-specific mortality: a correlated gamma-frailty model applied to mortality due to respiratory diseases in Danish twins born 1870-1930..  22:3873-3887. 2003
  • ROC methodology within a monitoring framework..  22:3473-3488. 2003
  • Comparing linear and nonlinear mixed model approaches to cosinor analysis.  22:3195-3211. 2003
  • A global sensitivity analysis of performance of a medical diagnostic test when verification bias is present..  22:2711-2721. 2003
  • Evaluating medical diagnostic tests at the subunit level in the presence of verification bias..  22:2161-2176. 2003
  • Power calculations for large multi-arm placebo-controlled studies of dichotomous outcomes..  22:1943-1954. 2003
  • Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen..  22:1457-1464. 2003
  • Sample size estimation for GEE method for comparing slopes in repeated measurements data..  22:1305-1315. 2003
  • A parametric model for long-term follow-up data from phase III breast cancer clinical trials..  22:339-352. 2003
  • Missing data in the 2 x 2 table: patterns and likelihood-based analysis for cross-sectional studies with supplemental sampling..  22:517-534. 2003
  • In vitro bioequivalence testing..  22:55-68. 2003
  • A practical approach for comparing means of two groups without equal variance assumption..  21:3137-3151. 2002
  • Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?.  21:2889-2897. 2002
  • Industry perspectives on ICH guidelines..  21:2949-2957. 2002
  • The ebb and flow of the NHS waiting list: how do recruitment and admission affect event-based measures of the length of 'time-to-admission'?.  21:2991-3009. 2002
  • A multistate model for the genetic analysis of the ageing process..  21:2511-2526. 2002
  • Reproducibility probability in clinical trials..  21:1727-1742. 2002
  • Individual bioequivalence testing under 2x3 designs..  21:629-648. 2002
  • Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head..  21:371-387. 2002
  • The impact of the international guideline entitled Statistical Principles for Clinical Trials (ICH E9)..  20:2549-2560. 2001
  • Using observational data to estimate prognosis: an example using a coronary artery disease registry..  20:2505-2532. 2001
  • Improving the fit of bivariate smoothing splines when estimating longitudinal immunological and virological markers in HIV patients with individual antiretroviral treatment strategies..  20:2489-2504. 2001
  • Evaluation of an adjusted chi-square statistic as applied to observational studies involving clustered binary data..  20:2149-2161. 2001
  • Sample size calculations for clustered binary data..  20:1971-1982. 2001
  • Testing for the presence of cured patients: a simulation study..  20:1783-1796. 2001
  • Two-phase shelf-life estimation..  20:1239-1248. 2001
  • Assessing human fertility using several markers of ovulation..  20:965-978. 2001
  • Bayesian analyses of longitudinal binary data using Markov regression models of unknown order..  20:755-770. 2001
  • Tests for 2 x K contingency tables with clustered ordered categorical data..  20:785-794. 2001
  • Detecting treatment-by-centre interaction in multi-centre clinical trials..  20:193-213. 2001
  • Strategic use of statistical thinking in drug development..  19:3211-3217. 2000
  • Individual bioequivalence: Preface.  19:2719. 2000
  • The bootstrap procedure in individual bioequivalence.  19:2741-2754. 2000
  • A small sample confidence interval approach to assess individual bioequivalence..  19:2885-2897. 2000
  • An individual bioequivalence criterion: regulatory considerations..  19:2821-2842. 2000
  • Preface. Bioequilavence measures..  19:2719. 2000
  • The bootstrap procedure in individual bioequivalence..  19:2741-2754. 2000
  • First steps in analysing NHS waiting times: avoiding the 'stationary and closed population' fallacy..  19:2037-2051. 2000
  • Modelling covariance structure in the analysis of repeated measures data..  19:1793-1819. 2000
  • Modelling the cumulative risk for a false-positive under repeated screening events..  19:1865-1879. 2000
  • On statistical analysis for placebo-challenging designs in clinical trials.  19:1029-1037. 2000
  • Generalized treatment effects for clinical trials..  19:887-899. 2000
  • On statistical analysis for placebo-challenging designs in clinical trials..  19:1029-1037. 2000
  • Accounting for unreported and missing intercourse in human fertility studies..  19:665-679. 2000
  • Comparison of diagnostic markers with repeated measurements: a non-parametric ROC curve approach..  19:511-523. 2000
  • Accounting for unreported and missing intercourse in human fertility studies.  19:665-679. 2000
  • Individual bioequivalence: Preface.  19:2719-. 2000
  • Prognostic models based on literature and individual patient data in logistic regression analysis..  19:141-160. 2000
  • The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials..  18:3435-3451. 1999
  • Evaluating the exposure and disease relationship with adjustment for different types of exposure misclassification: a regression approach..  18:2795-2808. 1999
  • Testing proportionality in the proportional odds model fitted with GEE.  18:1419-1433. 1999
  • Testing proportionality in the proportional odds model fitted with GEE..  18:1419-1433. 1999
  • Combining classification trees using MLE..  18:727-740. 1999
  • A regression model for multivariate random length data..  18:199-211. 1999
  • Combining classification trees using MLE.  18:727-740. 1999
  • Comparing risk-adjustment methods for provider profiling..  16:2645-2664. 1997
  • Discriminant analysis using the unweighted sum of binary variables: a comparison of model selection methods..  16:2679-2700. 1997
  • Bayesian inference in two-phase prevalence studies..  16:1121-1133. 1997
  • Statistical methods for two-sequence three-period cross-over designs with incomplete data..  16:1031-1039. 1997
  • A parametric approach to population bioequivalence..  16:441-454. 1997
  • Statistical methods for two-sequence three-period cross-over designs with incomplete data.  16:1031-1039. 1997
  • The impact of patient compliance on drug concentration profile in multiple doses..  15:659-669. 1996
  • Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.  15:361-387. 1996
  • Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors..  15:361-387. 1996
  • Polynomials with asymptotes for longitudinal data..  15:61-74. 1996
  • The impact of patient compliance on drug concentration profile in multiple doses.  15:659-669. 1996
  • A statistic for comparing two correlated markers which are prognostic for time to an event..  14:2217-2225. 1995
  • The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables..  14:2119-2129. 1995
  • Multi-state models and diabetic retinopathy.  14:1975-1983. 1995
  • Smoothing splines for longitudinal data.  14:1235-1248. 1995
  • Non-parametric estimation for the difference or ratio of median failure times for paired observations..  14:275-281. 1995
  • ON THE EFFICACY OF THE RANK TRANSFORMATION IN STEPWISE LOGISTIC AND DISCRIMINANT-ANALYSIS - REPLY.  13:1794-1795. 1994
  • SEQUENTIAL-METHODS BASED ON THE BOUNDARIES APPROACH FOR THE CLINICAL COMPARISON OF SURVIVAL TIMES - DISCUSSION.  13:1369-1370. 1994
  • Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer..  13:1313-1327. 1994
  • The case against independent monitoring committees..  13:1411-1414. 1994
  • Discussion of ‘sequential methods based on the boundaries approach for the clinical comparison of survival times’.  13:1369-1370. 1994
  • Two-stage sampling in pharmaceutical applications..  12:1999-2008. 1993
  • A survey of monitoring practices in cancer clinical trials..  12:435-450. 1993
  • Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations..  12:471-479. 1993
  • Discussion: Stephen George, a survey of monitoring practices in cancer clinical trials: Stephanie Green and John Crowley, data monitoring committees for Southwest Oncology Group clinical trials.  12:457-459. 1993
  • On the efficacy of the rank transformation in stepwise logistic and discriminant analysis..  12:143-151. 1993
  • ANALYZING THE RELATIONSHIP BETWEEN CHANGE IN A RISK FACTOR AND RISK OF DISEASE.  11:783-797. 1992
  • Analysing the relationship between change in a risk factor and risk of disease..  11:783-797. 1992
  • Application of empirical Bayes inference to estimation of rate of change in the presence of informative right censoring..  11:621-631. 1992
  • A comparison of several tests for censored paired data..  11:193-208. 1992
  • Correction: Outlier detection in bioavailability/bioequivalence studies (Statistics in Medicine (1990) 9 (549-558)).  11:425. 1992
  • Test for batch-to-batch variation in stability analysis..  11:269-270. 1992
  • On the estimation of total variability in assay validation..  10:1543-1553. 1991
  • Analyses of black and white differentials in the age trajectory of mortality in two closed cohort studies..  10:1043-1059. 1991
  • Methods for the analysis and assessment of clinical databases: the clinician's perspective..  10:617-628. 1991
  • Outlier detection in bioavailability/bioequivalence studies..  9:549-558. 1990
  • Test for batch-to-batch variation in stability analysis..  8:883-890. 1989
  • Beyond sensitivity, specificity and statistical independence.  7:1289-1295. 1988
  • Commentary. Response to Dr Halperin on ‘models of the interaction of mortality and the evolution of risk factor distribution: A general stochastic process formulation’.  7:293-295. 1988
  • Estimating hidden morbidity via its effect on mortality and disability..  7:325-336. 1988
  • Models of the interaction of mortality and the evolution of risk factor distribution: a general stochastic process formulation..  7:239-256. 1988
  • The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model..  4:39-46. 1985
  • Tying clinical research to patient care by use of an observational database..  3:375-387. 1984
  • Regression modelling strategies for improved prognostic prediction..  3:143-152. 1984
  • Strategies for analysing ecological health data: models of the biological risk of individuals..  1:163-181. 1982
  • Mantel-Haenszel statistics and direct standardization..  1:37-39. 1982
  • Robust analysis of secondary phenotypes in case-control genetic association studies 2016
  • Comparison of diagnostic markers with repeated measurements: A non- parametric ROC curve approach 2000
  • Discussion: Frank W Rockhold and G Enas, data monitoring and interim analyses in the pharmaceutical industry: Ethical and logistical considerations: George W Williams et al, monitoring of clinical trials and interim analyses from a drug sponsor's point of view 1993